SenoRx Prices Low

SenoRx Inc., an Aliso Viejo, Calif.-based provider of minimally-invasive medical devices for the diagnosis and treatment of breast cancer, priced 5.5 million common shares at $8 per share ($11-$13 range), for an IPO take of approximately $44 million. It will trade on the Nasdaq under ticker symbol SENO, while Banc of America Securities and Citigroup served as co-lead underwriters. The company had raised $54.57 million in total VC funding since its 1998 inception, from firms like MPM Capital, Domain Associates, Mayfield, Medicus Venture Partners, De Novo Ventures, Entrepreneurs' Fund and Tyco Capital (shares now held by Protostar Equity Partners).